S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Why Your IRA Could Crash on June 16th (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Why Your IRA Could Crash on June 16th (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Why Your IRA Could Crash on June 16th (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Why Your IRA Could Crash on June 16th (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Why Your IRA Could Crash on June 16th (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Why Your IRA Could Crash on June 16th (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Why Your IRA Could Crash on June 16th (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Why Your IRA Could Crash on June 16th (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
NASDAQ:AKTX

Akari Therapeutics (AKTX) Stock Forecast, Price & News

$0.18
-0.01 (-5.35%)
(As of 05/31/2023 ET)
Compare
Today's Range
$0.18
$0.19
50-Day Range
$0.15
$0.26
52-Week Range
$0.14
$1.61
Volume
219,876 shs
Average Volume
353,666 shs
Market Capitalization
$13.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.75

Akari Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,454.6% Upside
$2.75 Price Target
Short Interest
Healthy
0.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.48mentions of Akari Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

678th out of 1,006 stocks

Pharmaceutical Preparations Industry

345th out of 492 stocks


AKTX stock logo

About Akari Therapeutics (NASDAQ:AKTX) Stock

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Stock News Headlines

We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Update
See More Headlines
Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Company Calendar

Last Earnings
3/31/2020
Today
5/31/2023
Next Earnings (Estimated)
7/19/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKTX
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.75
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+1,454.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.02 per share

Miscellaneous

Free Float
28,440,000
Market Cap
$13.17 million
Optionable
Not Optionable
Beta
1.31

Key Executives

  • Rachelle Jacques
    President, Chief Executive Officer & Director
  • Melissa Bradford-Klug
    Chief Operating Officer
  • Torsten Hombeck
    Chief Financial & Accounting Officer
  • Miles Nunn
    Chief Scientific Officer
  • John F. Neylan
    Chief Medical Officer & Executive Vice President













AKTX Stock - Frequently Asked Questions

Should I buy or sell Akari Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AKTX shares.
View AKTX analyst ratings
or view top-rated stocks.

What is Akari Therapeutics' stock price forecast for 2023?

2 Wall Street research analysts have issued twelve-month price targets for Akari Therapeutics' stock. Their AKTX share price forecasts range from $1.50 to $4.00. On average, they anticipate the company's share price to reach $2.75 in the next twelve months. This suggests a possible upside of 1,454.6% from the stock's current price.
View analysts price targets for AKTX
or view top-rated stocks among Wall Street analysts.

How have AKTX shares performed in 2023?

Akari Therapeutics' stock was trading at $0.4699 at the start of the year. Since then, AKTX shares have decreased by 62.4% and is now trading at $0.1769.
View the best growth stocks for 2023 here
.

Are investors shorting Akari Therapeutics?

Akari Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 228,600 shares, an increase of 104.5% from the April 30th total of 111,800 shares. Based on an average trading volume of 485,100 shares, the days-to-cover ratio is presently 0.5 days.
View Akari Therapeutics' Short Interest
.

When is Akari Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 19th 2023.
View our AKTX earnings forecast
.

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) issued its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.25.

What other stocks do shareholders of Akari Therapeutics own?
What is Akari Therapeutics' stock symbol?

Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."

Who are Akari Therapeutics' major shareholders?

Akari Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (10.67%) and Renaissance Technologies LLC (0.38%).
View institutional ownership trends
.

How do I buy shares of Akari Therapeutics?

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akari Therapeutics' stock price today?

One share of AKTX stock can currently be purchased for approximately $0.18.

How much money does Akari Therapeutics make?

Akari Therapeutics (NASDAQ:AKTX) has a market capitalization of $13.17 million. The biopharmaceutical company earns $-17,750,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

How can I contact Akari Therapeutics?

Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The official website for the company is www.akaritx.com. The biopharmaceutical company can be reached via phone at 442080040261, via email at info@akaritx.com, or via fax at 646-843-9352.

This page (NASDAQ:AKTX) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -